Zacks Research Analysts Reduce Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for Corcept Therapeutics in a report issued on Wednesday, January 14th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings of ($0.31) per share for the quarter, down from their previous forecast of $0.04. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at ($0.06) EPS and FY2026 earnings at $0.43 EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. HC Wainwright dropped their price target on shares of Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Canaccord Genuity Group decreased their price objective on Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Truist Financial set a $50.00 price target on Corcept Therapeutics in a report on Wednesday, December 31st. Finally, Wall Street Zen cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $80.83.

Corcept Therapeutics Trading Down 1.9%

Corcept Therapeutics stock opened at $34.73 on Monday. The company has a market cap of $3.65 billion, a P/E ratio of 39.47 and a beta of 0.23. Corcept Therapeutics has a 1 year low of $32.99 and a 1 year high of $117.33. The firm’s 50-day moving average is $68.28 and its 200-day moving average is $71.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The firm had revenue of $207.64 million during the quarter, compared to analyst estimates of $223.78 million. During the same quarter in the previous year, the business posted $0.41 EPS. Corcept Therapeutics’s revenue was up 13.8% compared to the same quarter last year.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CORT. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics during the third quarter valued at about $25,000. Clearstead Advisors LLC raised its holdings in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 193 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at approximately $28,000. Hantz Financial Services Inc. boosted its stake in Corcept Therapeutics by 598.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 395 shares during the period. Finally, Larson Financial Group LLC boosted its stake in Corcept Therapeutics by 2,326.3% in the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 442 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other news, CEO Joseph K. Belanoff sold 40,000 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the completion of the sale, the chief executive officer directly owned 2,701,370 shares of the company’s stock, valued at $215,488,284.90. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $35.18, for a total value of $703,600.00. Following the completion of the transaction, the insider owned 1,235 shares in the company, valued at $43,447.30. The trade was a 94.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 194,500 shares of company stock valued at $14,186,410. 20.50% of the stock is currently owned by corporate insiders.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.